VILPs stimulate human cells to produce insulin-like hormones

In an unexpected finding, scientists have identified four viruses that can produce insulin-like hormones that are active on human cells. The discovery brings new possibilities for revealing biological mechanisms that may cause diabetes or cancer.

“Our research may help open up a new field that we might call microbial endocrinology,” says Dr Emrah Altindis, a Joslin research fellow. “We show that these viral insulin-like peptides can act on human and rodent cells. With the very large number of microbial peptides to which we are exposed, there is a novel window for host-microbe interactions. We hope that studying these processes will help us to better understand the role of microbes in human disease.”

“Indeed, the discovery of the viral insulin-like hormones raises the question of what their role might be in diabetes, as well as autoimmune disease, cancer and other metabolic conditions,” says Dr C. Ronald Kahn, Joslin’s chief academic officer and senior author on the paper.

The key idea for the investigation came when Dr Altindis, whose previous research focused on creating vaccines against bacteria, attended a Joslin seminar that discussed potential causes of the autoimmune reaction that drives type 1 diabetes. He began to hypothesise whether bacteria or viruses could create insulin-like peptides (small versions of proteins) that could help to trigger the disease.

By analysing large public research databases that hold viral genomic sequences, he and his colleagues at Joslin found that various viruses can produce peptides that are similar in whole or in part to 16 human hormones and regulatory proteins.

“What really caught our attention were four viruses that had insulin-like sequences,” says Dr Kahn.

These viruses were from a family of viruses known to infect fish. To find out if they could be active in mammals, the Joslin team collaborated with Richard DiMarchi, Professor of Chemistry at Indiana University, whose lab chemically synthesised these viral insulin-like peptides (VILPs).

Experimenting in mouse and human cells, the scientists studied whether the VILPs could act like hormones. Their experiments proved that the VILPs could indeed bind to human insulin receptors and receptors for a closely related hormone called IGF-1 (insulin-like growth factor 1). These are the critical proteins on the cells that tell them to take up glucose and to grow. Additionally, the peptides could stimulate all of the signalling pathways inside the cells that were stimulated by human insulin and IGF-1. And mice injected with the viral peptides exhibited lower levels of blood glucose, another sign of insulin action. Moreover, analysis of databases of viruses found in the human intestine showed evidence that humans are exposed to these viruses.

“These viruses are definitely known to infect fish and amphibians, but they are not known to infect humans,” Dr Kahn points out. “However, it’s possible that humans get exposed to these viruses through just eating fish. Nobody has checked directly whether under some conditions the viruses could either infect cells or be at least partly absorbed through the gut intestine.”

The scientists now will broaden their search for other viruses that produce human-like hormones. “This finding is the tip of an iceberg,” Dr Kahn says. “There are thought to be more than 300,000 viruses that can infect or be carried in mammals, and only 7,500 or so of these, or about 2.5%, have been sequenced. Thus, we certainly expect to find many more viral hormones, including more viral insulins, in the future.”

“This research also opens up a new aspect to study in type 1 diabetes and autoimmunity,” he says. “It may be that these or similar microbial insulin-like molecules could be an environmental trigger to start the autoimmune reaction in type 1 diabetes. On the other hand, you could also imagine that this might desensitise the immune response and could be protective.”

A similar question is open for metabolic diseases such as type 2 diabetes and obesity, in which the body fails to respond properly to insulin. “You could envision that these viral peptides could either protect from or contribute to insulin resistance,” Dr Kahn says.

These or similar viruses might also be a factor in certain human cancers. “If these viruses are inside the gut, could the VILPs they produce stimulate the growth of gut cells so that you get polyps or tumours of the gut?” Dr Kahn asks. “Or if they’re absorbed or become infectious, could they infect any organ in the body?”

Analysing such viral peptides may eventually help drug companies to design new forms of synthesised human insulins. “We might be able to learn something, for example, about making insulins that don’t need refrigeration and can be stored for long periods of time, or insulins that are absorbed more quickly or degrade more slowly,” he suggests.

Given Dr Altindis’s earlier research on infectious disease rather than in endocrinology, “our discovery gives an example of how work in one field can stimulate thought in another field,” Dr Kahn adds. “It really underlines the importance of cross-fertilisation in the scientific discovery process, which is so valuable but so underappreciated.”